255 related articles for article (PubMed ID: 33313384)
1. Targeting of Nanotherapeutics to Infection Sites for Antimicrobial Therapy.
Dong X; Zhang CY; Jin G; Wang Z
Adv Ther (Weinh); 2019 Nov; 2(11):. PubMed ID: 33313384
[TBL] [Abstract][Full Text] [Related]
2. Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management.
Zhang CY; Gao J; Wang Z
Adv Mater; 2018 Oct; 30(43):e1803618. PubMed ID: 30203430
[TBL] [Abstract][Full Text] [Related]
3. Macromolecular Nanotherapeutics and Antibiotic Adjuvants to Tackle Bacterial and Fungal Infections.
Dey R; Mukherjee S; Barman S; Haldar J
Macromol Biosci; 2021 Nov; 21(11):e2100182. PubMed ID: 34351064
[TBL] [Abstract][Full Text] [Related]
4. Nanotherapeutic provides dose sparing and improved antimicrobial activity against Brucella melitensis infections.
Lueth P; Haughney SL; Binnebose AM; Mullis AS; Peroutka-Bigus N; Narasimhan B; Bellaire BH
J Control Release; 2019 Jan; 294():288-297. PubMed ID: 30572034
[TBL] [Abstract][Full Text] [Related]
5. Neutrophils and Macrophages as Targets for Development of Nanotherapeutics in Inflammatory Diseases.
Su Y; Gao J; Kaur P; Wang Z
Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33348630
[TBL] [Abstract][Full Text] [Related]
6. An experimental analysis of the curative action of penicillin in acute bacterial infections. III. The effect of suppuration upon the antibacterial action of the drug.
SMITH MR; WOOD WB
J Exp Med; 1956 Apr; 103(4):509-22. PubMed ID: 13306859
[TBL] [Abstract][Full Text] [Related]
7. Developing Novel Host-Based Therapies Targeting Microbicidal Responses in Macrophages and Neutrophils to Combat Bacterial Antimicrobial Resistance.
Watson K; Russell CD; Baillie JK; Dhaliwal K; Fitzgerald JR; Mitchell TJ; Simpson AJ; Renshaw SA; Dockrell DH
Front Immunol; 2020; 11():786. PubMed ID: 32582139
[TBL] [Abstract][Full Text] [Related]
8. Infection-activated lipopeptide nanotherapeutics with adaptable geometrical morphology for in vivo bacterial ablation.
Yu QH; Huang R; Wu KY; Han XL; Cheng YJ; Liu WL; Zhang AQ; Qin SY
Acta Biomater; 2022 Dec; 154():359-373. PubMed ID: 36191775
[TBL] [Abstract][Full Text] [Related]
9. Antibody Treatment against Angiopoietin-Like 4 Reduces Pulmonary Edema and Injury in Secondary Pneumococcal Pneumonia.
Li L; Foo BJW; Kwok KW; Sakamoto N; Mukae H; Izumikawa K; Mandard S; Quenot JP; Lagrost L; Teh WK; Singh Kohli G; Zhu P; Choi H; Buist ML; Seet JE; Yang L; He F; Kwong Chow VT; Tan NS
mBio; 2019 Jun; 10(3):. PubMed ID: 31164474
[TBL] [Abstract][Full Text] [Related]
10. Nanotherapeutics with immunoregulatory functions for the treatment of bacterial infection.
Yang D; Ding M; Song Y; Hu Y; Xiu W; Yuwen L; Xie Y; Song Y; Shao J; Song X; Dong H
Biomater Res; 2023 Jul; 27(1):73. PubMed ID: 37481650
[TBL] [Abstract][Full Text] [Related]
11. Cell membrane-coated nanoparticles for the treatment of bacterial infection.
Ma J; Jiang L; Liu G
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Sep; 14(5):e1825. PubMed ID: 35725897
[TBL] [Abstract][Full Text] [Related]
12. Formulation of host-targeted therapeutics against bacterial infections.
Varma DM; Zahid MSH; Bachelder EM; Ainslie KM
Transl Res; 2020 Jun; 220():98-113. PubMed ID: 32268128
[TBL] [Abstract][Full Text] [Related]
13. Smart Multifunctional Polymer Systems as Alternatives or Supplements of Antibiotics To Overcome Bacterial Resistance.
Pranantyo D; Zhang K; Si Z; Hou Z; Chan-Park MB
Biomacromolecules; 2022 May; 23(5):1873-1891. PubMed ID: 35471022
[TBL] [Abstract][Full Text] [Related]
14. Nanomaterials for alternative antibacterial therapy.
Hemeg HA
Int J Nanomedicine; 2017; 12():8211-8225. PubMed ID: 29184409
[TBL] [Abstract][Full Text] [Related]
15. Host and Pathogen-Directed Therapies against Microbial Infections Using Exosome- and Antimicrobial Peptide-derived Stem Cells with a Special look at Pulmonary Infections and Sepsis.
Moosazadeh Moghaddam M; Fazel P; Fallah A; Sedighian H; Kachuei R; Behzadi E; Imani Fooladi AA
Stem Cell Rev Rep; 2023 Oct; 19(7):2166-2191. PubMed ID: 37495772
[TBL] [Abstract][Full Text] [Related]
16. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
17. Nano-fats for bugs: the benefits of lipid nanoparticles for antimicrobial therapy.
Thorn CR; Thomas N; Boyd BJ; Prestidge CA
Drug Deliv Transl Res; 2021 Aug; 11(4):1598-1624. PubMed ID: 33675007
[TBL] [Abstract][Full Text] [Related]
18. Novel Nanotherapeutics as Next-generation Anti-infective Agents: Current Trends and Future Prospectives.
Subhaswaraj P; Syed A; Siddhardha B
Curr Drug Discov Technol; 2020; 17(4):457-468. PubMed ID: 31309893
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Targeting of the Host-Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs.
Munguia J; Nizet V
Trends Pharmacol Sci; 2017 May; 38(5):473-488. PubMed ID: 28283200
[TBL] [Abstract][Full Text] [Related]
20. Technologies to address antimicrobial resistance.
Baker SJ; Payne DJ; Rappuoli R; De Gregorio E
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):12887-12895. PubMed ID: 30559181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
